Vermillion Reports Landmark OVA1 Cost-Effectiveness Analysis Compared to Current Standard at ACMQC

By: via Benzinga
Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced initial results ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.